Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Humanized Target Gene Disease Models
Transform uncertainty into genetically precise solutions. Engineer humanized targets for CAR-T, PD-1, or hematologic studies with TurboKnockout® technology—accelerating your path to actionable insights.

Clinically Validated Systems
Streamline testing of oncology, immunotherapies, and hematologic drugs in pre-validated, humanized environments.
Accelerated Model Development
Achieve 50% faster model delivery through gene-based engineering, outpacing traditional methods.
Custom Human Gene Integration
Seamlessly replace animal genes with human sequences to replicate disease mechanisms with unmatched accuracy.
Overview
Product
FAQs
Overview
Accelerate Therapeutic Validation with Human-Relevant Precision
Leverage cutting-edge gene-engineered models powered by TurboKnockout® to validate CAR-T, PD-1, and hematologic therapies in systems that mirror human biology—translating results into clinically actionable insights.
Explore Ready-to-Use Mouse Models
Discover over 18,000 validated mouse strains—including knockout, conditional knockout, and humanized models—covering 20+ research areas such as oncology, neurology, and metabolism. All models are supported by detailed genotype data and guaranteed quality, helping you fast-track discovery with confidence.
You Might Also Be Interested In
MouseAtlas Model Library
Search and access curated genetically engineered mouse strains
Oncology CRO Platform
End-to-end preclinical oncology support from models to IND data
Cardiometabolic CRO Platform
IND-ready studies using genetic and induced disease models
Gene Therapy CRO Platform
AI-guided AAV design and full-spectrum preclinical validation
Autoimmune & Inflammation CRO Platform
Advancing autoimmune drug discovery with models and efficacy data.
Rodent Breeding
Scalable colony expansion with full genotyping support
Product
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Quantity
Main Area of Research
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Selection Made Simple
Access Our Model Library >>
Base Strain
Catalog Number
Catalog NumberNameBase StrainResearch ApplicationAction
I001220B6-hPCSK9/Apoe KOC57BL/6CyaDevelopment, screening, and preclinical evaluation of PCSK9-targeted drugs；Research on metabolic diseases such as hyperlipidemia, stroke, coronary heart disease, familial hypercholesterolemia (FH), and other atherosclerotic cardiovascular diseases (ASCVD)
C001601B6-hGLP-1R/obC57BL/6NCya;C57BL/6JCyaInvestigation of the pathogenesis of obesity and type 2 diabetes；Development and screening of drugs for obesity and type 2 diabetes；Research on other metabolic diseases such as cardiovascular and myocardial diseases；Study of the neuroprotective effect in nervous system diseases
C001779B6-hFOLH1 (hPSMA) C57BL/6NCyaFOLH1-targeted drug screening, development, and evaluation；Research on the pathological mechanisms and therapeutic approaches of hyperhomocysteinemia；Research on the pathological mechanisms and therapeutic approaches of various solid tumors like prostate cancer
C001787B6-hLAG3C57BL/6JCyaLAG3-targeted drug screening, development, and evaluation；Research on the pathological mechanisms and therapeutic approaches of malignant tumors such as melanoma, colorectal cancer, and non-small cell lung carcinoma；Research on the pathological mechanisms and therapeutic approaches of chronic infections including HIV infection, hepatitis B, and tuberculosis；Research on the pathological mechanisms and therapeutic approaches of autoimmune diseases like rheumatoid arthritis and Hashimoto's thyroiditis
C001783B6-hFAPC57BL/6NCyaFAP-targeted drug screening, development, and evaluation；Research on the pathological mechanisms and therapeutic approaches of malignant tumors
C001588TG-hAPOC3C57BL/6NCyaDevelopment, screening, and preclinical efficacy evaluation of therapeutics targeting human APOC3；Investigation of the pathogenic mechanisms and therapeutic strategies for hypertriglyceridemia (HTG)
C001804B6-hIL2C57BL/6NCyaIL2-targeted drug screening, development, and evaluation；Research on the pathological mechanisms and therapeutic approaches of certain cancers；Research on the pathological mechanisms and therapeutic approaches of autoimmune disorders, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, Sjögren's syndrome, multiple sclerosis, and type 1 diabetes
C001817B6-hCD28C57BL/6NCyaCD28-targeted drug screening, development, and evaluation；Research on the pathological mechanisms and therapeutic approaches of autoimmune disorders such as rheumatoid arthritis, Sjogren's syndrome, and systemic sclerosis；Research on the transplant rejection；Research on the pathological mechanisms and therapeutic approaches of certain cancers；Research on the pathological mechanisms and therapeutic approaches of chronic infections like HIV
C001235B6-hPDL1-V(2)C57BL/6JCyaDevelopment and screening of PD-L1-targeted drugs；Efficacy and safety evaluation of PD-L1-targeted drugs；Evaluation of tumor immunotherapy；Research on the immune system and tumor immune escape mechanisms
C001797BALB/c-hIL13BALB/cAnCyaIL13-targeted drug screening, development, and evaluation；Research on the pathological mechanisms and therapeutic approaches of allergic and inflammatory diseases；Research on parasitic infections and fibrotic diseases
Items: 1 to 10 of 115
1
2
3
4
5
6
...
11
12
Previous Page
Next Page
FAQs
Frequently Asked Questions (FAQs)
Can models combine multiple genes (e.g., CD47 + SIRPα)?
Multiplex Humanization: Models like B6-hCD47/hSIRPα demonstrate 4.7-fold increased tumor clearance with dual blockade.
Conditional Systems: Tissue-specific co-expression (e.g., Tet-On) ensures <2% leaky expression.
How does TurboKnockout-Pro® minimize mosaicism in sickle cell models?
High-Fidelity Editing: eSpCas9(1.1) reduces off-target effects by >95%.
ESC Cloning: Achieve >90% germline transmission and screen for variants via 30x WGS.
How is the mouse strain selected for rare neurological disorders?
Mechanism-Driven Choice: Prioritize strains like C57BL/6J-SOD1G93A for ALS.
Genetic Purity: Backcross humanized alleles into >98% pure backgrounds.
Phenotypic Screening: Pre-screen strains to identify clinically relevant modifiers.
How do you validate human protein expression levels (e.g., PD-L1)?
Transcriptomic: NanoString® analysis confirms mRNA within ±15% of human baselines.
Proteomic: Flow cytometry benchmarks PD-L1 density to clinical samples (2,000–5,000 molecules/cell).
Functional: Anti-PD-1 response correlation of R²=0.78 with clinical data.
Can you share CAR-T toxicity data from models like B6-hCD47?
Off-Target Effects: B6-hCD47 models showed <5% off-target lysis of CD47+ stromal cells (7-AAD/Annexin V assays).
CRS Correlation: Humanized IL6/IL6R models achieved 89% alignment between murine cytokine spikes and clinical CRS grading.
How do you ensure humanized gene functionality in complex diseases like leukemia?
Our multi-tiered validation strategy ensures functional fidelity:
Pathway Alignment: Retain murine regulatory elements (e.g., promoters) while replacing coding sequences with human counterparts, mitigating interspecies discrepancies in pathways like JAK-STAT.
Functional Testing: Validate via CAR-T efficacy assessments and PDX engraftment, as demonstrated in RIKEN’s ALL studies.
Receptor-Ligand Compatibility: Co-humanize interacting pairs (e.g., PD-1/PD-L1) to preserve binding affinity.
What Customers Say About Cyagen
Violet Shimmer
Stanford University
The service provided to us by Cyagen is now in press at Nature as an article.
Scarlett Rouge
Seattle Children’s Hospital
We are very pleased with the state-of-the-art professional transgenic services provided by Cyagen for our study published recently in Nature. We continue to use Cyagen’s transgenic services as it allows us to do better and more efficient research with transgenic mice.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
Contact Information
Full Name
Email
Phone Number
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research